The U.S. Food and Drug Administration issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program. The application was filed on January 13, 2026. In the clinical trial data submitted to the agency, a remarkable 76% of previously untreated patients had a substantial decrease in...
The U.S. Food and Drug Administration issued a Request for Information (RFI) seeking public comment on potential new standards for in-home opioid disposal products. This effort is part of the agency’s broader work to combat the opioid crisis. Companies selling opioid analgesics are currently required to make available prepaid mail-back envelopes to outpatient...
Study Results on the New Endometrial Cancer Drug Researchers studied sacituzumab govitecan (SG) as a possible treatment for advanced endometrial cancer (EC) in patients who had already undergone chemotherapy and immunotherapy. The study was part of the TROPiCS-03 trial, which included patients with various metastatic solid tumors. In this phase II study, 41...
What the Research Revealed About Saliva and Glucose Monitoring Scientists developed a new type of glucose sensor called a BioTFT (Biosensing Thin-Film Transistor) that can detect glucose in saliva instead of blood. This technology is non-invasive, meaning it does not require a blood sample, and it provides results in less than 60...
The U.S. Food and Drug Administration approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1). This action reflects the agency’s commitment to accelerating cures and expanding treatment options including for...
What if weight loss didn’t have to mean losing muscle? A new early research phase 2 clinical trial published in Nature Medicine tested a powerful idea: combine the currently available drug semaglutide, a GLP-1 weight-loss medication, with a second drug called bimagrumab, which is still experimental and currently not FDA approved, to see if patients could lose more fat while keeping more muscle. The results suggest this combination could change how we think about obesity treatment.